Senators question Allergan CEO on tribe patent deal
Por um escritor misterioso
Descrição
A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.
Prescription Drug Costs
Pharma's contentious inter partes reviews come under Supreme Court scrutiny
Allergan Gains Another Approval for Botox Amid Patent Controversy Over Restasis - Xtalks
How to Protect a Drug Patent? Give It to a Native American Tribe - The New York Times
Allergan plc
With new bill, Sen. McCaskill looks to end 'brazen' tribal licensing strategy Allergan started
Judge asks if Allergan's patent deal with Mohawk tribe is a 'sham
All eyes on Saint Regis Mohawk Tribe in contentious patent case
Judge asks if Allergan's patent deal with Mohawk tribe is a 'sham
Supreme Court case could deal a blow to Mohawk tribe's patent plan
Allergan CEO Defends Mohawk Tribe Restasis Patent Deal
Page 67 – Business North Carolina
Allergan does patent deal for Restasis with Native American tribe
A handful of Allergan's top shareholders want to bring back the old CEO as chairman
Supreme Court sends Allergan packing over Restasis tribal licensing strategy
de
por adulto (o preço varia de acordo com o tamanho do grupo)
